Uncategorized

Axes, Rage, and VR at DiaPharma?

It’s Not Just Support. It’s Solutions.


  diapharma

Kicking off 2023

Axes, rage, and VR at DiaPharma? At our national sales meeting, there is!

DiaPharma held our national sales meeting in January – it’s a chance to see each other in person, plan the year ahead, and have some fun! DiaPharma staff tried our hands at axe throwing, virtual reality, and “rage room”. Congrats to customer service specialist Amy on her bullseye!

genesis amy

rage

Meet us in person at the following events:

  • Hemostasis and Thrombosis Research Society (HTRS) Scientific Symposium: March 10 – 12 in Orlando, FL
  • Society of Toxicology (SOT) ToxExpo: March 20 – 22 in Nashville, TN
  • Anticoagulation Forum: April 1 – 3 in San Francisco, CA
  • American Association for Cancer Research (AACR): April 14 – 19 in Orlando, FL
  • International Society for Laboratory Hematology (ISLH): May 11 – 13 in New Orleans, LA
  • American Thoracic Society (ATS): May 19 – 24 in Washington, DC
  • International Society for Thrombosis and Hemostasis (ISTH): June 24 – 28 in Montréal, Quebec

Diapharma Meet Us - Make an Appointment

Diapharma Find Your Territory Manager

we deliver solutions

It’s Not Just Support. It’s Solutions.

Over 25 years of scientific expertise, just a call or click away.

Diapharma Jen Mike

Visit diapharma.com

Copyright © 2022 DiaPharma Group, Inc. All rights reserved.

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-00-01012Rev01

Complimentary Webinar: “Shearly You Can’t Be Serious! T-TAS® 01 for Total Platelet Function”

It’s Not Just Support. It’s Solutions.


  diapharma

You’re invited to a complimentary webinar:

Shearly you can’t be serious!

T-TAS® 01 for total platelet function

 

REGISTER DIAPHARMA

total platelet function

T-TAS® 01 PL Assay:

One test, one result, one answer for total platelet function

Help address staffing and budgetary challenges with a frontline test for overall total platelet function

  • Detects dysfunction due to anti-platelet therapy, and impaired primary hemostasis such as von Willebrand Disease (vWD)
  • Activated by shear stress, not agonist
  • Simultaneously handles multiple samples
  • Useful and easy-to-interpret results
  • Improve efficiency of additional testing
  • Provide more information than a pathway-specific test

T-TAS

REGISTER DIAPHARMA


It’s Not Just Support. It’s Solutions.

Over 25 years of scientific expertise, just a call or click away.

Connect with a DiaPharma Scientist

diapharma bioassays hemostasis thrombosis chromogenic

Visit diapharma.com

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-08-00049Rev01

Clot Club #38

CHOOSING WISELY – COAGULATION TESTING RECOMMENDATIONS

Complimentary Webinar: “Shearly You Can’t Be Serious! T-TAS® 01 for Total Platelet Function”

It’s Not Just Support. It’s Solutions.


  diapharma

You’re invited to a complimentary webinar:

Shearly you can’t be serious!

T-TAS® 01 for total platelet function

REGISTER DIAPHARMA

total platelet function

T-TAS® 01 PL Assay:

One test, one result, one answer for total platelet function

Help address staffing and budgetary challenges with a frontline test for overall total platelet function

  • Single assay with easy-to-interpret test result provides simple and comprehensive platelet reactivity status
  • Get a better clinical picture using true physiological flow/shear rates
  • T-TAS® 01 analyzer is low-cost, takes up modest space in the lab, and is uncomplicated to learn and operate
  • Allows direct comparison of the effect of antiplatelet therapies across different combinations and classes (i.e. aspirin ± P2Y12 inhibitors)

T-TAS

REGISTER DIAPHARMA


It’s Not Just Support. It’s Solutions.

Over 25 years of scientific expertise, just a call or click away.

Connect with a DiaPharma Scientist

diapharma bioassays hemostasis thrombosis chromogenic

Visit diapharma.com

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-08-00047Rev01

Clot Club #37

A STEEEEP LEARNING CURVE: MY TAKE HOME MESSAGES FROM AN ALCOHOL-ASSOCIATED LIVER DISEASE MEETING FROM A NEWBIE

Clot Club #36

THE DEBATE OF EARLY-LIVER TRANSPLANTATION FOR ALCOHOL-ASSOCIATED LIVER DISEASES

Because matrix matters! The path to lung disease is paved with MMPs and collagen

It’s Not Just Support. It’s Solutions.


  diapharma

DiaPharma and QuickZyme Know Matrix Matters!

QuickZyme specializes in collagen assays and MMP activity assays (MMP-2, MMP-7, MMP-8, MMP-9, MMP-14). These assays were developed by scientists to fill an unmet need as an alternative to laborious methods. The assays give a more granular insight to the role that extracellular matrix remodeling can play in fibrosis, inflammation, and metastatic tumors.

MMPs degrade collagen, elastin, and proteoglycans. As indicators of inflammation and disease, they are key targets for drug development.

  • Idiopathic pulmonary fibrosis (IPF): MMP-7 plays a role in the development of scarring in the lungs and may predict a decline of lung function.
  • Chronic obstructive pulmonary disease (COPD): Circulating MMP-9 is linked with increased exacerbation risk.
  • Cystic fibrosis (CF): MMP-7, MMP-8, and MMP-9 may play an important role in the injury/repair response in CF.
  • Lymphangioleiomyomatosis (LAM): MMP-2 and MMP-7 are expressed and contribute to the destruction of lung tissue in LAM.
  • Cigarette smoke: MMP-1, -2, -7, -9 and -12 have all been implicated in tissue damage due to cigarette smoke, but MMP-12 has been the most extensively studied.

Finally, a test to accurately and specifically quantify MMP activity in relevant biological samples (blood, sputum, urine, cell cultures, etc.). These kits make testing more efficient, with a dual readout option: Measure endogenous active (naturally occurring) or total (active + pro) MMP for each plate.

QuickZyme

Learn More


Make your life easier with these QuickZyme MMP Activity Assays:

Research use only in the U.S. and Canada. Not for use in diagnostic procedures.


More to Explore

DiaPharma offers an extensive portfolio of pulmonary biomarkers, including Cytokeratin 18 (CK18, K18) ELISAs – M30® and M65®, ProAxsis Neutrophil Elastase Activity Kit, IMD Neutrophil Elastase ELISA Kit, ProAxsis Proteinase 3 Activity Kit, IMD Proteinase 3 ELISA kit, Quickzyme Total Collagen Kit, IMD Alpha 1 Antitrypsin (A1AT), and IQ Macro163™ ELISA.

READ MORE


diapharma

It’s Not Just Support. It’s Solutions.

Celebrating 25 years of scientific expertise, just a call or click away.

diapharma bioassays hemostasis thrombosis chromogenic

diapharma

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-00-01000Rev01

Connect with DiaPharma at ASH 2022 in New Orleans

It’s Not Just Support. It’s Solutions.


  diapharma

SEE US AT ASH 2022!

DiaPharma continues to celebrate 25 years in the hemostasis and coagulation field – team members will be attending ASH 2022 in New Orleans this year. Our goal is to learn all the new things and meet up with existing and potential customers.

We’re interested in topics like:

  • Gene therapy studies related to hemophilia, sickle cell disease, hereditary angioedema
  • TMA updates and therapeutic strategies
  • Platelet function related to thrombocytopenia
  • Bleeding and clotting disorders
  • Hemophilia diagnostics and treatment strategies

Reach out to Ryan McCaw or Elizabeth Mihal to set up a conversation about:

  • ADAMTS13 assays for activity, antigen or inhibitor testing*
  • The Total Thrombus formation Analysis System (T-TAS®) 01 for an IVD global platelet function test
  • Chromogenic FVIII and FIX* activity testing
  • HbS and HbF antibodies for flow cytometry
  • The ATLAS PST* system for unique platelet function testing based on contractile force measurements and machine learning

*For research use only. Not for use in diagnostic procedures.

Our team is eager to talk all things bleeding & clotting, and demo new technology in platelet function measurement.

Diapharma ISTH 2022

endothelial cell activation adamts13 vwf factor viii platelet function chromogenic assays anticoagulation testing doac complement c1-inhibitor macro163

*Research use only in U.S. and Canada. Not for use in diagnostic procedures.

diapharma


It’s Not Just Support. It’s Solutions.

Celebrating 25 years of scientific expertise, just a call or click away.

diapharma bioassays hemostasis thrombosis chromogenic

diapharma

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-00-00998Rev01

Tissue-Specific Biomarkers for Liver Injury in Gene Therapy Research

Studying liver toxicity in gene therapy research?

liver toxicity in gene therapy

Emerging Exploratory Biomarkers for Drug Safety Studies

Improve Early DILI/DIKI Prediction Increased Tissue Specificity

  • K18 (M65®)
  • ccK18 (M30®)
  • L-FABP
  • α-GST
  • NGAL/Lipocalin-2
  • Osteopontin
  • Cystatin C
  • α-Klotho

liver toxicity in gene therapy

ELISAs for Drug-Induced Liver Injury (DILI)

Biomarker Sample Type Description Available Assay Product #
Keratin 18 (K18) Serum or plasma Highly specific biomarker for hepatocyte cell death (necrosis and apoptosis)

Peviva M65® ELISA

Peviva M65 EpiDeath® ELISA

P10020

P10040

Caspase-cleaved Keratin 18 (ccK18) Serum or plasma Highly specific specific biomarker for hepatocyte apoptosis Peviva M30 Apoptosense® P10011
Osteopontin (OPN) Serum or plasma Biomarker for hepatic inflammation and necrosis

Osteopontin

Osteopontin N-Half

DPG27158

DPG27258

Alpha Glutathione S-Transferase (a-GST) Serum or plasma Short half-life; sensitive to rapid changes in liver damage TECO® Alpha GST TE1056
Liver Fatty Acid Binding Protein (L-FABP, FABP1) Serum or plasma Sensitive marker for hepatic injury (leakage) Diapharma L-FABP DPGLFABP

Research use only in the U.S. and Canada. Not for use in diagnostic procedures.

NOGGIN MEF ELISA

Over 20 years of scientific expertise,
with support just a call or click away.

Visit diapharma.com

Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

ML-00-00615Rev01

NASH-TAG (Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis) Conference 2019

Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis

Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis
Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis
Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis

 


Diapharma will attend NASH-TAG 2019 this year. Please click here to schedule a meeting with us or email us directly.

Learn from the leading researchers in NASH and Liver Fibrosis at NASH-TAG 2019


NASH-TAG = THERAPEUTIC AGENTS for NON-ALCOHOLIC STEATOHEPATITIS


About NASH-TAG

The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis. NASH-TAG 2019 will take place over two days providing attendees an understanding of current and future directions in diagnostic procedures, prospects and challenges in drug discovery and development for both NASH and liver fibrosis. Internationally renowned faculty will assist in the development of the educational content and will serve as faculty at the conference.


NASH-TAG Topics will include

  • MGL 3196 – a beta thyroid hormone receptor selective agonist
  • Aramchol – SCD1 modulator
  • NGM 282 – FGF19 construct
  • GS 9674 FXR – second generation FXR agonist
  • Selective PPAR modulators, hepatic and metabolic effects
  • Interactive Dialog on NASH Topics
  • Mitochrnodrial uncoupling as a pharmacological target in NASH
  • Extracellular vesticles as mediators of inflammation
  • Singnals form peclinical models and success of NASH trials
  • 3D Trissue modeling and precision cut liver slices: Will they help drug testing for NASH?
  • Barriers to overcome for reimbursement of NASH drugs
  • Lessons learned fromt he reimbursement of diabetes and CV drugs
  • Forecasting how the NASH market will develop in the US
  • Pros in clinical trials of NASH
  • Current and future trends in hepatic MRI using a background of cardiac MRI development
  • Assessing DILI in NASH trials
  • Genetic testing: Any use of sub phenotyping or risk stratification in clinical trials?
  • Update from EASL & AASLD
  • Understanding the methods of and need for CV risk assessment
  • Second harmonic generation fully quantitative histopathology assessment for NASH
  • GLP1R agonist compounds
  • GLP1 – glucagon receptor dual agonists
  • FGF21 – GLP1 dual agonism
  • Integrin antgonism as an anti-fibrotoic therapy
  • GPR40 and 84G cell coupled receptor modulators, BPI-4050
  • P2x7 – puringergic receptor antagoist

Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis
Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis
Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis

NASH-TAG | Facebook | Twitter | LinkedIn | The Chateaux Deer Valley